文献速递淋巴瘤白血病

慢性淋巴细胞白血病未竟事业:实现治愈的转化与临床优先方向

Unfinished business in chronic lymphocytic leukemia: translational and clinical priorities for a cure.
PubMed 文献 · Blood · 2026-01-01

综述指出靶向治疗已显著延长慢性淋巴细胞白血病(CLL)患者生存并实现长期疾病控制,但治愈仍罕见,尤其在高危组如TP53异常、对BTK与BCL-2抑制剂双重耐药或转化为侵袭性淋巴瘤者。文章强调感染、自身免疫和继发肿瘤仍显著影响发病与死亡,需研究免疫功能障碍与疾病异质性,以推动更广泛亚组治愈。

要点

  • 靶向治疗使CLL长期控制成为可能,但治愈仍限于极少数患者。
  • TP53异常、BTK与BCL-2抑制剂双重耐药及组织转化者预后仍差。
  • 感染、自身免疫和继发肿瘤仍是CLL主要发病与死亡原因。

核心结论

  • CLL靶向治疗已显著延长生存并实现长期疾病控制,但可靠清除疾病仍难以实现,治愈结局仍属例外。
  • 缩小发现科学与剩余临床挑战之间的差距,需聚焦免疫功能障碍、疾病异质性与治疗耐药的机制研究。

研究设计与样本

  • 本文为综述,围绕CLL治愈所面临的转化与临床优先方向进行论述。

主要发现

  • 靶向治疗大幅延长CLL患者生存,但高危组如TP53异常、对BTK与BCL-2抑制剂双重耐药或转化为侵袭性淋巴瘤者治愈仍罕见。
  • CLL被视为癌症相关免疫缺陷的模型,新冠大流行期间CLL患者感染与不良结局风险极高。
  • 感染、自身免疫和继发肿瘤相关并发症持续显著贡献CLL的发病与死亡。
  • 疾病进展与治疗耐药存在显著异质性,需机制研究阐明不同生物学模式。

临床怎么用

  • 临床应重视CLL患者感染、自身免疫和继发肿瘤的监测与管理。
  • 对TP53异常、BTK与BCL-2抑制剂双重耐药或组织转化患者,需探索更有效治愈策略。

局限性

  • 本文为综述性论述,未报告原始研究数据或系统检索方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Remarkable progress in the understanding of disease pathogenesis and treatment across hematologic malignancies has been achieved in the past 2 decades. Nevertheless, the reliable elimination of disease remains elusive for many cancers. Chronic lymphocytic leukemia (CLL) exemplifies the needs that must be addressed to close the gap between discovery science and the remaining clinical challenges. In CLL, targeted therapies have substantially prolonged survival and enabled long-term disease control for many patients. However, curative outcomes remain exceptional, particularly in high-risk groups such as those with TP53 disruption, dual resistance to Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors, or transformation to aggressive lymphoma. Recent insights into the interconnection between cancer and immunity have positioned CLL as a model example of cancer-associated immunodeficiency, a realization brought into sharp focus by the severe acute respiratory syndrome coronavirus 2 pandemic during which patients with CLL were at extremely high-risk for infection and poor outcomes. Therefore, complications related to infections, autoimmunity, and secondary cancers continue to contribute substantially to morbidity and mortality, underscoring the need for research on immune dysfunction in CLL. Furthermore, pronounced heterogeneity in disease progression and therapeutic resistance highlight the need for mechanistic studies to clarify these distinct biological patterns. Advances in these areas not only hold the promise of curative therapy for broader patient subgroups in CLL but will also inform innovation in research on other cancers, particularly in establishing a molecular definition of disease and defining those interactions with the underlying and resultant immune deficiencies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wu CJ, Caligaris-Cappio F, Chiorazzi N, et al. Unfinished business in chronic lymphocytic leukemia: translational and clinical priorities for a cure. Blood. 2026. PMID: 42018659. doi:10.1182/blood.2025032393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。